Monte Rosa Q3 net loss widens, but revenue increases on Novartis payment

Monte Rosa Therapeutics

06/11/2025 12:20

Overview

Monte Rosa Q3 net loss widens to $27.1 mln, driven by increased R&D expenses

Collaboration revenue for Q3 rises to $12.8 mln, up from $9.2 mln year-over-year

Monte Rosa receives $120 mln upfront payment from Novartis, boosting cash reserves

Outlook

Monte Rosa expects MRT-8102 Phase 1 data in H1 2026

Company plans to present MRT-2359 data by year-end 2025

Monte Rosa's cash position expected to fund operations through 2028

Result Drivers

NOVARTIS COLLABORATION - Second agreement with Novartis provides $120 mln upfront payment and potential for up to $5.7 bln in total deal value

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$12.77 mln
Q3 Net Income
-$27.08 mln
Q3 Operating Expenses
$45.74 mln
Q3 Operating Income
-$32.98 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Monte Rosa Therapeutics Inc is $17.00, about 27.6% above its November 5 closing price of $12.31

Press Release: ID:nGNX77njlt

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)